A blood test caught 90% of aggressive prostate cancers, against 74% for the standard PSA.

The standard PSA test has anchored prostate cancer screening for decades, but it has a well-known weakness: it flags plenty of men who do not have aggressive disease while sometimes missing cancers that do need treatment. A large Swedish study now suggests a newer blood test can narrow that gap significantly, catching far more of the cancers that actually matter without a corresponding jump in unnecessary follow-up testing.

The research adds fresh evidence to a debate that has simmered in urology for years, over whether prostate-specific antigen testing alone is precise enough for modern screening, or whether it is time to layer in additional biomarkers that can better separate dangerous tumors from ones unlikely to ever cause harm.

What the study compared

According to reporting on the research, published June 23 in the Annals of Internal Medicine, researchers in Sweden tested more than 12,600 men between the ages of 50 and 74 using both the standard PSA blood test and a newer test called Stockholm3, then tracked the men for two years through national cancer registries to see which diagnoses actually followed. That national-registry follow-up gives the comparison a level of real-world validation that a single-clinic study typically cannot match, since it captures diagnoses regardless of where in the country a participant was eventually treated.

During that two-year window, 443 of the men in the study were diagnosed with aggressive prostate cancer. Researchers compared how well each test had flagged those specific men as high-risk at the outset, rather than simply comparing how many men each test flagged overall.

The numbers behind the headline

The Stockholm3 test identified 90% of the men who went on to be diagnosed with aggressive prostate cancer, compared with 74% for the standard PSA test working alone, according to the study results. That 16-percentage-point gap represents a meaningful number of aggressive cancers that PSA testing alone would have missed at the point of initial screening, cases that might not have been flagged for biopsy or closer monitoring until later, when the disease had potentially progressed further.

Just as significant, according to the researchers, the newer test did not achieve that higher detection rate by simply flagging more men overall. The study found Stockholm3 identified a similar number of men as high risk who ultimately did not have aggressive disease, meaning the improved detection did not come at the cost of a sharply higher false-positive rate, one of the central complaints urologists have long raised about relying on PSA alone.

What separates Stockholm3 from a standard PSA test

A standard PSA test measures a single protein in the blood, prostate-specific antigen, and flags elevated levels as a signal warranting further investigation. That single-marker approach is part of why PSA testing struggles with precision: elevated PSA can result from prostate cancer, but it can also result from an enlarged prostate, inflammation or infection unrelated to cancer at all, generating false alarms that lead to unnecessary biopsies.

Stockholm3 was developed to address that limitation by combining PSA measurement with additional biomarkers and clinical risk factors into a single risk score, an approach designed to give physicians a more complete picture of an individual patient’s likelihood of harboring aggressive disease rather than relying on one protein level in isolation.

What the data does not yet show

Researchers involved in the study were direct about the limits of what a two-year registry follow-up can demonstrate. A more precise blood test could, in principle, enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures men undergo after an ambiguous PSA result. But the study’s authors also noted that longer-term follow-up is still needed to determine whether using Stockholm3 instead of, or alongside, PSA actually improves survival and other patient outcomes over time, rather than simply flagging aggressive cancers earlier on paper.

That distinction matters because earlier detection does not automatically translate into better outcomes for every patient. Some prostate cancers grow so slowly that earlier detection changes little about a man’s eventual prognosis, which is part of why prostate cancer screening guidelines have shifted over the past decade toward more individualized risk assessment rather than blanket testing recommendations for all men past a certain age.

What it could mean for prostate cancer screening going forward

For now, the study functions as a strong data point in favor of biomarker-enhanced screening rather than a finalized recommendation to replace PSA testing nationwide. Broader adoption of tests like Stockholm3 would likely depend on additional trials, cost considerations for healthcare systems, and guidance from professional urology and oncology bodies about how such tests should fit into existing screening protocols.

Men with questions about which prostate cancer screening approach is appropriate for their individual risk factors, including family history and age, are generally advised to discuss the options directly with a physician rather than substitute a specific test based on a single study, since screening decisions typically weigh multiple factors beyond any one test’s detection rate.

How this fits into the long-running debate over PSA screening

Standard PSA screening has been debated within urology and primary care for more than a decade, largely because of the same tension this new study addresses directly: the test is good at flagging elevated risk broadly but poor at distinguishing which of those flagged men actually have cancer requiring treatment versus a slow-growing form unlikely to ever cause harm. That imprecision led several major medical organizations to walk back blanket PSA screening recommendations in past years, shifting toward more individualized conversations between patients and physicians about the tradeoffs of testing.

A test like Stockholm3, if it becomes more widely available, could change that calculus by giving physicians a tool that better separates aggressive disease from indolent cases before recommending a biopsy, potentially restoring some of the confidence in routine screening that PSA’s imprecision had eroded. Whether it reaches that level of adoption will likely depend on additional research, cost considerations, and how quickly professional guidelines incorporate newer biomarker-based tests into standard screening pathways.

Morning Overview produced this article with AI assistance and reviewed it against the cited sources.

More from Morning Overview